BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LBL-034 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LBL-034\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06049290-3140@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:LBL-034: Phase 1/2 readout est. (NCT06049290)
DESCRIPTION:LBL-034\, phase 1/2\, Multiple Myeloma.\nStudy: A Clinical Tria
 l of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma\nEstima
 ted primary completion: 20 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lbl-034#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06049290
URL:https://assetmemo.bio/drug/lbl-034#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
